Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 114

1.

Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer.

Prodosmo A, Buffone A, Mattioni M, Barnabei A, Persichetti A, De Leo A, Appetecchia M, Nicolussi A, Coppa A, Sciacchitano S, Giordano C, Pinnarò P, Sanguineti G, Strigari L, Alessandrini G, Facciolo F, Cosimelli M, Grazi GL, Corrado G, Vizza E, Giannini G, Soddu S.

J Exp Clin Cancer Res. 2016 Sep 6;35(1):135. doi: 10.1186/s13046-016-0410-3.

2.

Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers.

Bon G, Loria R, Azzurra Amoreo C, Verdina A, Sperduti I, Mastrofrancesco A, Soddu S, Grazia Diodoro M, Mottolese M, Todaro M, Stassi G, Milella M, De Maria R, Falcioni R.

Oncotarget. 2016 Aug 19. doi: 10.18632/oncotarget.11400. [Epub ahead of print]

3.

Epitelial-to-mesenchimal transition and invasion are upmodulated by tumor-expressed granzyme B and inhibited by docosahexaenoic acid in human colorectal cancer cells.

D'Eliseo D, Di Rocco G, Loria R, Soddu S, Santoni A, Velotti F.

J Exp Clin Cancer Res. 2016 Feb 2;35:24. doi: 10.1186/s13046-016-0302-6.

4.

Apoptosis induced by a HIPK2 full-length-specific siRNA is due to off-target effects rather than prevalence of HIPK2-Δe8 isoform.

Di Rocco G, Verdina A, Gatti V, Virdia I, Toietta G, Todaro M, Stassi G, Soddu S.

Oncotarget. 2016 Jan 12;7(2):1675-86. doi: 10.18632/oncotarget.6423.

5.

hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.

Trono P, Di Modugno F, Circo R, Spada S, Di Benedetto A, Melchionna R, Palermo B, Matteoni S, Soddu S, Mottolese M, De Maria R, Nisticò P.

Oncogene. 2016 Feb 18;35(7):887-96. doi: 10.1038/onc.2015.143. Epub 2015 May 11.

PMID:
25961924
6.

MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response.

Mancini F, Pieroni L, Monteleone V, Lucà R, Fici L, Luca E, Urbani A, Xiong S, Soddu S, Masetti R, Lozano G, Pontecorvi A, Moretti F.

Oncogene. 2016 Jan 14;35(2):228-40. doi: 10.1038/onc.2015.76. Epub 2015 May 11.

7.

Prognostic role of serum p53 antibodies in lung cancer.

Mattioni M, Soddu S, Prodosmo A, Visca P, Conti S, Alessandrini G, Facciolo F, Strigari L.

BMC Cancer. 2015 Mar 18;15:148. doi: 10.1186/s12885-015-1174-4.

8.

HIPK2 deficiency causes chromosomal instability by cytokinesis failure and increases tumorigenicity.

Valente D, Bossi G, Moncada A, Tornincasa M, Indelicato S, Piscuoglio S, Karamitopoulou ED, Bartolazzi A, Pierantoni GM, Fusco A, Soddu S, Rinaldo C.

Oncotarget. 2015 Apr 30;6(12):10320-34.

9.

Abscopal effect of radiation therapy: interplay between radiation dose and p53 status.

Strigari L, Mancuso M, Ubertini V, Soriani A, Giardullo P, Benassi M, D'Alessio D, Leonardi S, Soddu S, Bossi G.

Int J Radiat Biol. 2015 Mar;91(3):294. doi: 10.3109/09553002.2014.997514. Epub 2015 Feb 4. No abstract available.

PMID:
25650895
10.

HIPK2 sustains apoptotic response by phosphorylating Che-1/AATF and promoting its degradation.

De Nicola F, Catena V, Rinaldo C, Bruno T, Iezzi S, Sorino C, Desantis A, Camerini S, Crescenzi M, Floridi A, Passananti C, Soddu S, Fanciulli M.

Cell Death Dis. 2014 Sep 11;5:e1414. doi: 10.1038/cddis.2014.381.

11.

Mutant cohesin drives chromosomal instability in early colorectal adenomas.

Cucco F, Servadio A, Gatti V, Bianchi P, Mannini L, Prodosmo A, De Vitis E, Basso G, Friuli A, Laghi L, Soddu S, Fontanini G, Musio A.

Hum Mol Genet. 2014 Dec 20;23(25):6773-8. doi: 10.1093/hmg/ddu394. Epub 2014 Jul 30.

12.

Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist.

Ubertini V, Norelli G, D'Arcangelo D, Gurtner A, Cesareo E, Baldari S, Gentileschi MP, Piaggio G, Nisticò P, Soddu S, Facchiano A, Bossi G.

Oncogene. 2015 May 7;34(19):2493-504. doi: 10.1038/onc.2014.191. Epub 2014 Jul 7.

PMID:
24998848
13.

Abscopal effect of radiation therapy: Interplay between radiation dose and p53 status.

Strigari L, Mancuso M, Ubertini V, Soriani A, Giardullo P, Benassi M, D'Alessio D, Leonardi S, Soddu S, Bossi G.

Int J Radiat Biol. 2014 Mar;90(3):248-55. doi: 10.3109/09553002.2014.874608. Epub 2014 Feb 6. Erratum in: Int J Radiat Biol. 2015 Mar;91(3):294.

PMID:
24350918
14.

ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.

Gilardini Montani MS, Prodosmo A, Stagni V, Merli D, Monteonofrio L, Gatti V, Gentileschi MP, Barilà D, Soddu S.

J Exp Clin Cancer Res. 2013 Nov 19;32:95. doi: 10.1186/1756-9966-32-95.

15.

Pax8 has a critical role in epithelial cell survival and proliferation.

Di Palma T, Filippone MG, Pierantoni GM, Fusco A, Soddu S, Zannini M.

Cell Death Dis. 2013 Jul 18;4:e729. doi: 10.1038/cddis.2013.262.

16.

IMP-3 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study.

Soddu S, Di Felice E, Cabras S, Castellanos ME, Atzori L, Faa G, Pilloni L.

Eur J Histochem. 2013 Feb 14;57(1):e6. doi: 10.4081/ejh.2013.e6.

17.

HIPK2 catalytic activity and subcellular localization are regulated by activation-loop Y354 autophosphorylation.

Siepi F, Gatti V, Camerini S, Crescenzi M, Soddu S.

Biochim Biophys Acta. 2013 Jun;1833(6):1443-53. doi: 10.1016/j.bbamcr.2013.02.018. Epub 2013 Feb 26.

18.

p53 centrosomal localization diagnoses ataxia-telangiectasia homozygotes and heterozygotes.

Prodosmo A, De Amicis A, Nisticò C, Gabriele M, Di Rocco G, Monteonofrio L, Piane M, Cundari E, Chessa L, Soddu S.

J Clin Invest. 2013 Mar;123(3):1335-42. doi: 10.1172/JCI67289. Epub 2013 Feb 1.

19.

Serum p53 antibody detection in patients with impaired lung function.

Mattioni M, Chinzari P, Soddu S, Strigari L, Cilenti V, Mastropasqua E.

BMC Cancer. 2013 Feb 6;13:62. doi: 10.1186/1471-2407-13-62.

20.

Updates on HIPK2: a resourceful oncosuppressor for clearing cancer.

D'Orazi G, Rinaldo C, Soddu S.

J Exp Clin Cancer Res. 2012 Aug 13;31:63. doi: 10.1186/1756-9966-31-63. Review.

Items per page

Supplemental Content

Write to the Help Desk